Identifying the mechanisms behind non-apoptotic functions of mitochondrial matrix-localized MCL-1

确定线粒体基质定位的 MCL-1 非凋亡功能背后的机制

基本信息

项目摘要

PROJECT SUMMARY Aberrant regulation of apoptosis is a hallmark of human pathologies, including neurodegeneration, autoimmunity, and cancer. Intrinsic apoptosis is regulated by the BCL-2 family which is composed of anti-apoptotic proteins (e.g., BCL-2 and MCL-1) which sequester pro-apoptotic BH3-only proteins (e.g., BIM and BAD) or directly inhibit pro-apoptotic effectors, BAX and BAK, preventing their oligomerization. Many cancer cells overexpress anti- apoptotic proteins to promote aberrant survival. MCL-1 is unique among anti-apoptotic proteins because it is essential in early embryonic development and for the survival of many cell lineages (e.g., hematopoietic stem cells, lymphocytes, neutrophils, neurons, and cardiomyocytes). Our lab previously reported that MCL-1 has two isoforms –– one that localizes to the outer mitochondrial membrane (OMM) and one that localizes to the mitochondrial matrix. Although OMM MCL-1’s canonical anti-apoptotic function has been well characterized, the roles of matrix MCL-1 are still largely unknown. Evidence suggests that matrix MCL-1 serves to maintain normal mitochondrial fission/fusion, oxidative phosphorylation, and cristae ultrastructure. The basis for these physiologic roles of MCL-1 remains unknown. Metabolomic investigation of Mcl1–deficient (Mcl1–/–) murine embryonic fibroblasts (MEFs) and MEFs lacking matrix-localized Mcl1 revealed that they are highly sensitive to glutamine deprivation as compared to wild-type MEFs. Additionally, MCL-1 protein levels decrease after 24 hours of glutamine withdrawal in wild-type MEFs. These data suggest a link between MCL-1 and glutamine metabolism that could be connected to the mitochondrial defects that are observed upon Mcl1 deletion. The goal of this proposal is to determine the functions of matrix MCL-1 and gain a mechanistic understanding of these functions. I hypothesize that matrix-localized MCL-1 plays an essential, non-apoptotic role in maintaining mitochondrial morphology and bioenergetics. To address this hypothesis, I will use a novel mutant mouse that endogenously expresses a truncated MCL-1 protein (MCL-1OM) which blocks apoptosis but cannot be imported into the mitochondrial matrix. First, I will ectopically express Mcl1 mutants back into Mcl1–/– MEFs to determine which version(s) of Mcl1 can rescue the death triggered by glutamine withdrawal. I will also perform mRNA-Seq on Mcl1–/–, Mcl1+/+, Mcl1–/+, and Mcl1–/OM MEFs to interrogate the metabolic rewiring induced by loss of matrix-localized MCL-1. Second, I will assess mitochondrial function (e.g., Seahorse XF Mito Stress Test and TMRE staining), determine the proteins interacting with matrix-localized MCL-1, ectopically express Opa1 and Drp1 mutants in Mcl1–/– MEFs, and perform confocal imaging on these cells to determine the functions of matrix- localized MCL-1 in mitochondrial morphology. Finally, I will perform in vivo experiments on Mcl1-/OM mice to analyze T cell activation, effector function, and memory T cell generation. These findings will provide new, mechanistic insights into the non-apoptotic roles of matrix-localized MCL-1 and could shed light on the potential consequences of using MCL-1 inhibitors for clinical applications.
项目摘要 凋亡的异常调节是人类病理的标志,包括神经变性,自身免疫性, 和癌症。固有凋亡受Bcl-2家族的调节,Bcl-2家族由抗凋亡蛋白组成 (例如,Bcl-2和MCl-1)哪个隔离pro-凋亡BH3仅蛋白质(例如BIM和坏蛋白)或直接抑制 促凋亡作用,Bax和Bak,以防止其低聚。许多癌细胞过表达抗 凋亡蛋白促进异常生存。 Mcl-1在抗凋亡蛋白中是独一无二的 早期胚胎发育和许多细胞谱系的生存至关重要(例如造血茎 细胞,淋巴细胞,神经粒,神经元和心肌细胞)。我们的实验室以前报道MCL-1有两个 同工型 - 一种定位于外部线粒体膜(OMM)的同工型,一种定位于 线粒体矩阵。尽管OMM MCL-1的规范抗凋亡功能已经很好地表征了 矩阵MCL-1的作用仍然很大未知。有证据表明矩阵MCL-1可以保持正常 线粒体裂变/融合,氧化磷酸化和Cristae超微结构。这些生理学的基础 MCL-1的角色仍然未知。 Mcl1-缺陷型(Mcl1 - / - )鼠类胚胎的代谢组研究 成纤维细胞(MEF)和缺乏基质量化MCL1的MEF显示它们对谷氨酰胺高度敏感 剥夺与野生型MEF相比。另外,24小时后MCL-1蛋白水平降低 野生型MEF的谷氨酰胺提取。这些数据表明MCL-1和谷氨酰胺代谢之间有联系 可以将其连接到MCL1缺失时观察到的线粒体缺陷。目标的目标 建议是确定矩阵MCL-1的功能并获得对这些功能的机械理解。 我假设基质定位的mcl-1在维持维持 线粒体形态和生物能学。为了解决这一假设,我将使用一种新型的突变鼠标 该内源表达截短的Mcl-1蛋白(MCL-1OM),该蛋白会阻塞凋亡,但不能是 进口到线粒体矩阵中。首先,我将向Mcl1突变体向MCL1 - / - MEFS表达 确定哪种版本的MCL1可以挽救谷氨酰胺提取触发的死亡。我也会表演 mcl1 –/ - ,mcl1+/+,mcl1 - /+和mcl1 - /om mefs上的mRNA-seq,以询问由损失引起的代谢重新布线 矩阵定位的mcl-1。第二,我将评估线粒体功能(例如,Seahorse XF Mito应力测试和 TMRE染色),确定与基质 - 定位Mcl-1相互作用的蛋白质,异位表达OPA1和 Mcl1 - / - MEF中的DRP1突变体,并在这些细胞上执行共共聚焦成像,以确定基质的功能 线粒体形态中的局部MCL-1。最后,我将在MCL1-/OM小鼠上进行体内实验 分析T细胞激活,效应子功能和记忆T细胞的产生。这些发现将提供新的 机械洞察基质化的MCL-1的非凋亡作用,并可能阐明电势 将MCL-1抑制剂用于临床应用的后果。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

Tristen Wright的其他基金

Identifying the mechanisms behind non-apoptotic functions of mitochondrial matrix-localized MCL-1
确定线粒体基质定位的 MCL-1 非凋亡功能背后的机制
  • 批准号:
    10676766
    10676766
  • 财政年份:
    2022
  • 资助金额:
    $ 4.28万
    $ 4.28万
  • 项目类别:

相似海外基金

Intra-Articular Drug Delivery Modulating Immune Cells in Inflammatory Joint Disease
关节内药物递送调节炎症性关节疾病中的免疫细胞
  • 批准号:
    10856753
    10856753
  • 财政年份:
    2023
  • 资助金额:
    $ 4.28万
    $ 4.28万
  • 项目类别:
Spatial genomic tools to interrogate T cell clonotypes, tumor clones and the microenvironment
用于询问 T 细胞克隆型、肿瘤克隆和微环境的空间基因组工具
  • 批准号:
    10565141
    10565141
  • 财政年份:
    2023
  • 资助金额:
    $ 4.28万
    $ 4.28万
  • 项目类别:
Heterogeneity and cellular hierarchy of lung cDC2
肺 cDC2 的异质性和细胞层次
  • 批准号:
    10665348
    10665348
  • 财政年份:
    2023
  • 资助金额:
    $ 4.28万
    $ 4.28万
  • 项目类别:
Tyk2 and Associated Cytokines in Salivary Gland Autoimmunity
Tyk2 和唾液腺自身免疫中的相关细胞因子
  • 批准号:
    10733367
    10733367
  • 财政年份:
    2023
  • 资助金额:
    $ 4.28万
    $ 4.28万
  • 项目类别:
Immunoregulatory Therapeutics for Ulcerative Colitis
溃疡性结肠炎的免疫调节治疗
  • 批准号:
    10697464
    10697464
  • 财政年份:
    2023
  • 资助金额:
    $ 4.28万
    $ 4.28万
  • 项目类别: